Authors:
Lyudmila BoyanovaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Lyudmila Boyanova in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-9622-0873
,
Galina GergovaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Galina Gergova in
Current site
Google Scholar
PubMed
Close
,
Nayden KandilarovDepartment of General and Hepatobiliary Pancreatic Surgery, Department of Surgery, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Nayden Kandilarov in
Current site
Google Scholar
PubMed
Close
,
Liliya BoyanovaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Liliya Boyanova in
Current site
Google Scholar
PubMed
Close
,
Daniel YordanovDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Daniel Yordanov in
Current site
Google Scholar
PubMed
Close
,
Raina GergovaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Raina Gergova in
Current site
Google Scholar
PubMed
Close
, and
Rumyana MarkovskaDepartment of Medical Microbiology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Rumyana Markovska in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

Prevalence of antibiotic resistant Helicobacter pylori was compared between 50 patients living outside the capital city and 50 matched pairs of capital city residents (CCRs). H. pylori isolates from 2018 to 2022 were included. Resistance rates in CCRs and those living elsewhere were 4.0 and 6.0% to amoxicillin, 48.0 and 42.0% to metronidazole, 30 and 30% to clarithromycin, and 4.0 and 4.0% to tetracycline, respectively. Levofloxacin resistance was higher (38.0%) in the capital city vs 20.0% (P = 0.047) in the country. Odd ratio for levofloxacin resistance between pair-matched groups was 2.45 (95% CI, OR 1.0–6.02, P value = 0.05) and relative risk for fluoroquinolone resistance was 1.90 (95% CI for RR 0.98–3.67) for CCRs vs residents in other regions. Resistance rates to levofloxacin and clarithromycin were worryingly high in our study, most probably due to the high quinolone consumption (2.86 DDD/day in 2017) in Bulgaria and the increase in macrolide, lincosamide and streptogramin consumption, especially of azithromycin, by >42% with the start of COVID-19 pandemic. Briefly, antibiotic resistance of H. pylori has a dynamic change, and it can display different patterns in certain geographic regions. The results imply that antibiotic consumption should be carefully controlled and unjustified use of levofloxacin should be restricted, especially in some large cities. Antibiotic policy should be further strengthened and regular monitoring of resistance in various geographic regions is needed for treatment optimization.

  • 1.

    Fischbach W, Malfertheiner P. Helicobacter pylori infection. Dtsch Arztebl Int 2018; 115(25): 429436. https://doi.org/10.3238/arztebl.2018.0429.

  • 2.

    Kuo CJ, Lee CH, Chang ML, Lin CY, Lin WR, Su MY, et al. Multidrug resistance: the clinical dilemma of refractory Helicobacter pylori infection. J Microbiol Immunol Infect 2021; 54(6): 11841187. https://doi.org/10.1016/j.jmii.2021.03.006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci 2014; 1: 19. https://doi.org/10.3389/fmolb.2014.00019.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance—from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021; 18(9): 613629. https://doi.org/10.1038/s41575-021-00449-x.

    • Search Google Scholar
    • Export Citation
  • 5.

    Domanovich-Asor T, Motro Y, Khalfin B, Craddock HA, Peretz A, Moran-Gilad J. Genomic analysis of antimicrobial resistance genotype-to-phenotype agreement in Helicobacter pylori. Microorganisms 2020; 9(1): 2. https://doi.org/10.3390/microorganisms9010002.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25(37): 55785589. https://doi.org/10.3748/wjg.v25.i37.5578.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Republic of Bulgaria, National Statistical Institute. https://www.nsi.bg/en/content/2981/population-towns-and-sex.

  • 8.

    Boyanova L, Ilieva J, Gergova G, Evstatiev I, Nikolov R, Mitov I. Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study. Folia Microbiol (Praha) 2013; 58(6): 587591. https://doi.org/10.1007/s12223-013-0251-9.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008; 60(4): 409415. https://doi.org/10.1016/j.diagmicrobio.2007.11.008.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    EUCAST - The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. http://www.eucast.org.

    • Search Google Scholar
    • Export Citation
  • 11.

    Högberg LD, Vlahović-Palčevski V, Pereira C, Weist K, Monnet DL; ESAC-Net study group, et al. Decrease in community antibiotic consumption during the COVID-19 pandemic, EU/EEA, 2020. Euro Surveill 2021; 26(46): 2101020. https://doi.org/10.2807/1560-7917.ES.2021.26.46.2101020.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Khouja T, Mitsantisuk K, Tadrous M, Suda KJ. Global consumption of antimicrobials: impact of the WHO global action plan on antimicrobial resistance and 2019 coronavirus pandemic (COVID-19). J Antimicrob Chemother 2022; 77(5): 14911499. https://doi.org/10.1093/jac/dkac028. PMID: 35178565.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Adriaenssens N, Bruyndonckx R, Versporten A, Hens N, Monnet DL, Molenberghs G, et al. Consumption of quinolones in the community, European union/European Economic area, 1997–2017. J Antimicrob Chemother 2021; 76(12 Suppl 2): ii37ii44. https://doi.org/10.1093/jac/dkab176.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Majalekar PP, Shirote PJ. Fluoroquinolones: blessings or curses. Curr Drug Targets 2020; 21(13): 13541370. https://doi.org/10.2174/1389450121666200621193355.

    • Search Google Scholar
    • Export Citation
  • 15.

    Kelly L, Schreiber YS, Hopko J, Kirkwood T, Kattini R, Poirier D, et al. Fluoroquinolone use in a rural practice. Can J Rural Med 2021; 26(1): 1418. https://doi.org/10.4103/cjrm.cjrm_67_20.

    • Search Google Scholar
    • Export Citation
  • 16.

    Gallini A, Taboulet F, Bourrel R. Regional variations in quinolone use in France and associated factors. Eur J Clin Microbiol Infect Dis 2012; 31(11): 29112918. https://doi.org/10.1007/s10096-012-1640-8.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Machado-Alba JE, Valladales-Restrepo LF, Gaviria-Mendoza A, Machado-Duque ME, Figueras A. Patterns of antibiotic prescription in Colombia: are there differences between capital cities and municipalities? Antibiotics (Basel) 2020; 9(7): 389. https://doi.org/10.3390/antibiotics9070389.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Vilaichone RK, Aumpan N, Ratanachu-Ek T, Uchida T, Tshering L, Mahachai V, et al. Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan. Int J Infect Dis 2020; 97: 102107. https://doi.org/10.1016/j.ijid.2020.05.077.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Bruinsma N, Hutchinson JM, van den Bogaard AE, Giamarellou H, Degener J, Stobberingh EE. Influence of population density on antibiotic resistance. J Antimicrob Chemother 2003; 51(2): 385390. https://doi.org/10.1093/jac/dkg072.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Zhen X, Chen J, Sun X, Sun Q, Guo S, Stålsby Lundborg C. Socioeconomic factors contributing to antibiotic resistance in China: a panel data analysis. Antibiotics (Basel) 2021; 10(8): 994. https://doi.org/10.3390/antibiotics10080994.

    • Search Google Scholar
    • Export Citation
  • 21.

    Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci 2015; 1354(1): 1231. https://doi.org/10.1111/nyas.12830.

  • 22.

    Lauener FN, Imkamp F, Lehours P, Buissonnière A, Benejat L, Zbinden R, et al. Genetic determinants and prediction of antibiotic resistance phenotypes in Helicobacter pylori. J Clin Med 2019; 8(1): 53. https://doi.org/10.3390/jcm8010053.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Losurdo G, Giorgio F, Pricci M, Girardi B, Russo F, Riezzo G, et al. Helicobacter pylori primary and secondary genotypic resistance to clarithromycin and levofloxacin detection in stools: a 4-year scenario in Southern Italy. Antibiotics (Basel) 2020; 9(10): 723. https://doi.org/10.3390/antibiotics9100723.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022; 37(9): 16661672. https://doi.org/10.1111/jgh.15917.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol 2020; 18(1): 8998. https://doi.org/10.1016/j.cgh.2019.03.048.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Kocsis B, Gulyás D, Szabó D. Delafloxacin, finafloxacin, and zabofloxacin: novel fluoroquinolones in the antibiotic pipeline. Antibiotics (Basel) 2021; 10(12): 1506. https://doi.org/10.3390/antibiotics10121506.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2021  
Web of Science  
Total Cites
WoS
696
Journal Impact Factor 2,298
Rank by Impact Factor Immunology 141/161
Microbiology 118/136
Impact Factor
without
Journal Self Cites
2,143
5 Year
Impact Factor
1,925
Journal Citation Indicator 0,39
Rank by Journal Citation Indicator Immunology 146/177
Microbiology 129/157
Scimago  
Scimago
H-index
29
Scimago
Journal Rank
0,362
Scimago Quartile Score Immunology and Microbiology (miscellaneous) (Q3)
Medicine (miscellaneous) (Q3)
Scopus  
Scopus
Cite Score
3,6
Scopus
CIte Score Rank
General Immunology and Microbiology 26/56 (Q2)
Infectious Diseases 149/295 (Q3)
Microbiology (medical) 66/118 (Q3)
Scopus
SNIP
0,598

2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
submission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2023 Online subsscription: 680 EUR / 832 USD
Print + online subscription: 760 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2022 0 0 0
Sep 2022 0 0 0
Oct 2022 0 0 0
Nov 2022 0 0 0
Dec 2022 0 0 0
Jan 2023 206 4 4
Feb 2023 0 0 0